for Prostate Brachytherapy
“The biggest concern was initially rectal dose,” Dr. Taylor said. “We realized that was not as big of a concern as originally thought. Dosimetry aspects were alleviated by seeing the planning in live time. Talking to a physician who had done several hundred implants with Cesium, he was seeing less urinary symptoms in his clinic. It confirmed someone treating patients consistently with Cesium were seeing benefits.”
In 2018, Dr. Bernard Taylor made the switch to Cesium as his isotope of choice for prostate brachytherapy. In this 30 minute webinar, he shared his experience including early concerns, elements critical to his successful, smooth transition.
What about logistics? What about dosimeter time frames and constraints? How have the early results and patient-reported outcomes compared to Iodine and Palladium?
Dr. Taylor was joined by Atef Omari, medical physicist with Bon Secours Health System and Paul Snyder, VP of Healthcare for Write2Market.
After nearly 10 years and more than 12,000 patients treated following its FDA approval for prostate cancer treatment, sufficient scientific data and patient-reported evidence suggest that Cesium-131 delivers equivalent to, or superior outcomes compared to Iodine and Palladium for both monotherapy and combination therapy. These results, including quick returns to baseline values and fast resolution of acute side effects, can be attributed to Cesium’s combination of high energy and short half-life effectively delivering a high dose of radiation more quickly for high-risk patients in a low dose rate setting.
Still, many radiation oncologists and urologists are reluctant to make the switch to Cesium due to concerns regarding planning, administrative burden and an “If it isn’t broken, don’t fix it,” position.
If you would like to know how easy it can be to put the power of Cesium to use in your practice contact:
Michael L. Krachon
VP Sales and Marketing